C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy

Kim, Woo Ram; Han, Yoon Dae; Min, Byung Soh

doi:10.1245/s10434-018-6828-4

Cited by 28 publications

(27 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, lower monocyte count is associated with better prognosis of localized CRC and metastatic disease [8][9][10][11] and was also con rmed as positive prognostic factor for TAS-102 in a study published by Kwakman and collaborators [7]. Similarly, elevated CRP levels are associated with poor prognosis of non-metastatic and metastatic CRC [12][13][14][15][16]. In our analysis, normal white blood count, neutrophil count, monocyte count, and lower NLR were associated with better treatment results.…”

Section: Discussionsupporting

confidence: 73%

Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

Grell

Dvořák

Vočka³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Trifluridine/tipiracil (TAS-102) is effective in refractory metastatic colorectal cancer (mCRC). Currently, no predictive biomarkers are established and used in clinical practice. Methods: We analyzed data of 160 patients treated with TAS-102 in real clinical practice in the Czech Republic. Different factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Median PFS was 3.3 months, and median OS 10.2 months. Factors significantly associated with PFS and/or OS were: ECOG performance status (PS), time from diagnosis of mCRC > 24 months, initiation of treatment > 3 months from last fluoropyrimidine, number of metastatic sites, baseline CRP level, WBC count, neutrophils count, monocytes count, neutrophil to lymphocyte ratio, development of neutropenia, thrombocytopenia, diarrhea, required dose reduction and cycle delay. We developed a scoring system TAScore from factors available at the beginning of treatment. One point each was assigned to the following factors (PS, diagnosis of mCRC > 24 months, initiation of TAS-102 > 3 months from fluoropyrimidine, baseline CRP, WBC, monocytes count < 0.5 × 10 9 /L) and patients were divided into 3 groups: high risk group (0 to 1 point), intermediate (2 to 3), favorable with 4 or more points. OS according to risk group was: 5.7 months for high risk, 8.7 for intermediate, 12.8 for favorable (P < 0.001). TAScore was also associated with PFS (P < 0.001). Conclusions : TAS-102 is effective in patients with refractory mCRC. We propose simple scoring system TAScore to help with precise patient selection at the beginning of TAS-102 treatment.

show abstract

Section: Discussionsupporting

confidence: 73%

Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

Grell

Dvořák

Vočka³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…There are increasing evidence manifested that systemic inflammation plays an important role in contributing the development and progression of malignancies [23]. Systemic inflammatory markers, such as CRP (C-reactive protein), was shown to be an independent predictor of poor outcome in patients suffered from various cancers [24][25][26]. A recent research unveiled that serum Apo-A1 levels showed strong negative correlation with systemic inflammatory markers including serum CRP and interleukin (IL)-8 levels and blood neutrophil count in 144 colorectal cancer patients [27], which indicate systemic inflammation may influence tumorigenesis and regulate lipid metabolism in the same period, thus, enabling some kinds of serum lipid markers to correlate with tumor characteristics and provide prognostic information.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

KEYWORDSPapillary thyroid cancer, serum lipid level, tumor size, lipid metabolism 2 Abstract Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC continued to increase over the past decades. Many studies showed that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is closely related with lipid metabolism, while the correlation between serum lipid and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC.Methods: We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E, Lp (a)) results, surgical records and pathological reports.Results: All these serum lipid biomarkers did not associated with tumor size in the female group. In the male group, on crude analysis, Apo-A1 and Lp (a) showed a marginally significant association with tumor size OR and 95% CI 0.158 (0.021-1.777), p=0.072; 0.997 (0.993-1.000) p=0.082 respectively.After adjusting for age and multifocality, Apo-A1 and Lp (a) showed a significant association with

show abstract

“…There are increasing evidence manifested that systemic in ammation plays an important role in contributing the development and progression of malignancies [19]. Systemic in ammatory markers, such as CRP (Creactive protein), was shown to be an independent predictor of poor outcome in patients suffered from various cancers [20][21][22]. A recent research unveiled that serum Apo-A1 levels showed strong negative correlation with systemic in ammatory markers including serum CRP and interleukin (IL)-8 levels and blood neutrophil count in 144 colorectal cancer patients [23], which indicate systemic in ammation may in uence tumorigenesis and regulate lipid metabolism in the same period, thus, enabling some kinds of serum lipid markers to correlate with tumor characteristics and provide prognostic information.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein A1 is A Protective Factor for Male Papillary Thyroid Cancer Patients. A Cross-Sectional Study of Single Academic Center in China.

Wang

Zhan-qiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Papillary thyroid cancer (PTC) is the most common type of thyroid cancer and the incidence of PTC has continued to increase over the past decades. Many studies have shown that obesity is an independent risk factor for PTC and obese PTC patients tend to have a relative larger tumor size and higher grade of tumor stage. Obesity is associated with disordered lipid metabolism and the relationship between serum lipids and PTC remains unclear. Therefore, this study aimed to investigate the association between serum lipid level and PTC.Methods: We retrospectively analyzed 1018 PTC patients diagnosed and treated in our hospital, all these cases were first diagnosed with PTC and had complete clinical information including ultrasound reports before surgery, serum lipid (CHOL, TG, HDL-c, LDL-c, Apo-A1, Apo-B, Apo-E) results, surgical records and pathological reports. Results: None of these lipid markers were associated with tumor size in the whole cohort and in the female group. In the male group, on crude analysis, Apo-A1 showed a marginally significant association with tumor size, [OR=0.158 (0.021-1.777)], p=0.072. After adjusting for age and multifocality, Apo-A1 showed a significant association with tumor size [OR=0.126 (0.016-0.974)], p=0.047. This association become more apparent in a young male subgroup, [OR=0.051 (0.005-0.497)], p=0.009. CHOL, TG, HDL-c, LDL-c, Apo-B, Apo-E did not show significant association with tumor size. As for LNM, neither in the male group nor in the female group were found to be associated with any serum lipid biomarkers.Conclusion: As PTC incidences continues to increase, our finding a negative association between PTC and apoA-1 imply that these lipids are protective factors for male PTC patients and provide us new clues about PTC and lipid metabolism, which may contribute to further investigation concerning diagnosing and preventing this most common type of thyroid cancer.

show abstract

C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy

Cited by 28 publications

References 31 publications

Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

Apolipoprotein A1 and lipoprotein(a) are protective factors for male papillary thyroid cancer patients. A cross-sectional study of single academic center in China.

Apolipoprotein A1 is A Protective Factor for Male Papillary Thyroid Cancer Patients. A Cross-Sectional Study of Single Academic Center in China.

Contact Info

Product

Resources

About